"From our perspective the one way to try and solve these issues is to eliminate the polymer and then once and for all we know if it's a drug issue or a polymer issue."

— Mark Landy, MD, president/CEO of MIV Therapeutics, commenting on reported results from the stent developer's first human trial, "JACC publishes MIV's VESTAsync trial results."

No Comments